Related Experiment Video
Updated: Jul 9, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and
Adam L Boxer1, Bradley F Boeve
1Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143-1207, USA. aboxer@memory.ucsf.edu
Abstract:
Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administration-approved medications for FTD although symptomatic treatments such as selective serotonin reuptake inhibitors and atypical antipsychotic agents are frequently used to manage behavioral abnormalities associated with this disorder. Evidence for the use of currently available symptomatic treatments in each FTD clinical subtype is reviewed. In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia
The progression of dementia is generally gradual.
Parkinson's Disease: Overview
